Lucence LiquidHallmark Expanded Assay

Lucence has launched an expanded version of its flagship LiquidHallmark liquid biopsy assay that includes both cell-free DNA and RNA profiling. The combined panel, available for US customers as a laboratory-developed test, includes cfRNA profiling of 27 actionable and emerging gene fusions and cfDNA profiling of mutations in 80 genes and fusions in 10 genes. The assay is powered by AmpliMark, the company’s proprietary amplicon-based sequencing technology, which uses molecular barcode and error-correction technology.